[go: up one dir, main page]

WO2009116078A3 - Oral dosage form containing a pyridinol derivative - Google Patents

Oral dosage form containing a pyridinol derivative Download PDF

Info

Publication number
WO2009116078A3
WO2009116078A3 PCT/IN2009/000115 IN2009000115W WO2009116078A3 WO 2009116078 A3 WO2009116078 A3 WO 2009116078A3 IN 2009000115 W IN2009000115 W IN 2009000115W WO 2009116078 A3 WO2009116078 A3 WO 2009116078A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
oral dosage
form containing
pyridinol derivative
pyridinol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000115
Other languages
French (fr)
Other versions
WO2009116078A2 (en
Inventor
Ashok Vasantray Vyas
Ravindra Tukaram Jadhav
Subhash Trimbak Phad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
M J BIOPHARM PVT Ltd
Original Assignee
M J BIOPHARM PVT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M J BIOPHARM PVT Ltd filed Critical M J BIOPHARM PVT Ltd
Priority to EP09722113A priority Critical patent/EP2265253A2/en
Priority to EA201001328A priority patent/EA201001328A1/en
Publication of WO2009116078A2 publication Critical patent/WO2009116078A2/en
Publication of WO2009116078A3 publication Critical patent/WO2009116078A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

An oral pharmaceutical composition comprising 3-hydroxy 2,4,6 trimethylpyridine, pharmaceutically acceptable salts, esters, derivatives and polymorphs thereof for the treatment of ischemia, intraocular hemorrhage and macular degeneration is disclosed.
PCT/IN2009/000115 2008-02-19 2009-02-19 Oral dosage formulations and process of preparation thereof Ceased WO2009116078A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09722113A EP2265253A2 (en) 2008-02-19 2009-02-19 Oral dosage form containing a pyridinol derivative
EA201001328A EA201001328A1 (en) 2008-02-19 2009-02-19 ORAL DOSED COMPOSITIONS AND METHOD FOR THEIR PRODUCTION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN357MU2008 2008-02-19
IN357/MUM/2008 2008-02-19

Publications (2)

Publication Number Publication Date
WO2009116078A2 WO2009116078A2 (en) 2009-09-24
WO2009116078A3 true WO2009116078A3 (en) 2010-01-07

Family

ID=41091338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000115 Ceased WO2009116078A2 (en) 2008-02-19 2009-02-19 Oral dosage formulations and process of preparation thereof

Country Status (3)

Country Link
EP (1) EP2265253A2 (en)
EA (1) EA201001328A1 (en)
WO (1) WO2009116078A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116077A2 (en) * 2008-02-19 2009-09-24 M.J.Biopharm Pvt. Ltd. Injectable preparations and a process of preparation thereof
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
ITMI20121916A1 (en) * 2012-11-09 2014-05-10 Velleja Res Srl FORMULATED WITH INTRA-GASTRIC ASSIGNMENT DELAYED BASED ON GLYCYRRHIZA GLABRA DERIVATIVES
KR101420315B1 (en) * 2014-03-19 2014-07-17 남봉길 Pharmaceutical liquid composition
CN104353107B (en) * 2014-11-10 2016-08-31 顾玉奎 A kind of medical sthptic sponge material and preparation method thereof
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
WO2022118217A1 (en) * 2020-12-01 2022-06-09 Apurve Mehra Treatment approach for coronaviruses using a herbal composition and a method of preparing said composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614857A1 (en) * 2004-05-12 2007-02-15 Marvel Lifesciences Limited Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614857A1 (en) * 2004-05-12 2007-02-15 Marvel Lifesciences Limited Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof

Also Published As

Publication number Publication date
EA201001328A1 (en) 2011-04-29
WO2009116078A2 (en) 2009-09-24
EP2265253A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2009116078A3 (en) Oral dosage form containing a pyridinol derivative
IL208896A (en) Derivatives of 6-(2-methyl-oxiranylmethyl)-[1,3] oxazinan-2-one and a process for their preparation
IN2012DN02968A (en)
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2011051490A3 (en) Heterocyclic derivatives
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2008020040A3 (en) 2,5-dihydroxybenzene compounds for the treatment of fibrosis
WO2008149382A8 (en) Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2008006795A3 (en) Indole compounds
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
EA200971086A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING SCHIZOPHRENIA
MX2012002528A (en) Therapeutic agent for mood disorders.
WO2009140341A3 (en) Atorvastatin compositions
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
EA200971087A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF ACUTE MANIA
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2009116076A3 (en) Ophthalmic preparation containing a pyridinol derivative
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
WO2008034912A3 (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
WO2008035305A3 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09722113

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009722113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201001328

Country of ref document: EA